RT Journal
A1 Mahadevia PJ, Makari D, Masaquel A
T1 MEthodological concerns regarding cost-effectiveness analysis of palivizumab in florida medicaid
JF Archives of Pediatrics & Adolescent Medicine
JO Archives of Pediatrics & Adolescent Medicine
YR 2012
FD October 1
VO 166
IS 10
SP 968
OP 970
DO 10.1001/archpediatrics.2012.1591
UL http://dx.doi.org/10.1001/archpediatrics.2012.1591
AB 
Hampp and colleagues1 present an economic analysis of palivizumab prophylaxis during the 2004-2005 respiratory syncytial virus (RSV) season in Florida using Medicaid claims data and assert that palivizumab prophylaxis is not cost-effective compared with no prophylaxis. Several important variables were not considered, which limits the scope of the investigators' conclusions. In addition, their analysis seemed to deviate from guidelines established by the US Panel on Cost-effectiveness in Health and Medicine.2